⌘K
Symbiotec Pharmalab is a research and development-driven pharmaceutical and biotechnology company, globally leading in corticosteroid and steroidal-hormone APIs. The IPO is a mix of fresh issue and offer for sale, with a significant portion being OFS. The company demonstrates consistent revenue and profit growth, healthy margins, and strong institutional interest.
The company's R&D focus and strategic expansion plans provide a solid foundation for future growth. Market sentiment is highly positive, evidenced by robust subscription figures across all categories and a healthy GMP, indicating strong demand for listing gains. While the valuation is at a slight premium, it is justified by the company's competitive advantages and growth prospects. Key risks such as customer/supplier concentration and regulatory challenges are present but appear manageable given the company's established position.
Strong market sentiment indicated by high GMP (18.72% premium) and robust subscription across all categories (overall 75.08x, QIB 181.2x, Retail 13.69x) suggests a high probability of listing gains.
The company's strong business fundamentals, global leadership, and positive market reception are likely to sustain investor interest post-listing, supporting short-term performance.
Symbiotec's R&D focus, expansion strategies into high-value APIs and complex injectables, and established global presence provide a solid foundation for long-term growth, despite a slightly premium valuation.
| Category | Shares Offered | % of Issue | Share |
|---|---|---|---|
| QIB | 88,76,516 | 49.91% | |
| NII (HNI) | 26,62,956 | 14.97% | |
| Retail | 62,13,563 | 34.93% | |
| Employee | 33,407 | 0.19% |
Premium gain of 18.72% over issue price.
Global leadership position in corticosteroid and steroidal-hormone APIs.
Research and development-driven, science-based pharmaceutical and biotechnology company.
Capabilities across organic chemistry, biotechnology, and complex injectables.
Product portfolio with regulated market approvals (USFDA, KFDA, Japan FDA, EDQM).
Long-standing relationships with domestic and global customer base.
Fully-invested, multi-scale, vertically integrated manufacturing platform.
Consistent revenue and EBITDA growth over the past three fiscal years.
Healthy and stable EBITDA and PAT margins.
Strong institutional interest with 34 anchor investors.
Successful expansion into new high-value APIs and complex injectables, increased global demand for APIs shifting away from China, and favorable regulatory environment.
Continued growth in existing API segments, stable customer relationships, and incremental product portfolio expansion.
Increased competition, adverse regulatory changes, supply chain disruptions, or significant customer losses.
Positive: Global leadership in corticosteroid and steroidal-hormone APIs (36.2% and 44.2% market share).
Concern: Slightly premium valuation with a post-IPO P/E of 56.81x and Price to Book of 5.35x.
Advisory: exit-heavy structure (OFS 91.5%, GCP-led objects; long-term capped at Neutral)
Listing-gain vs long-term: Apply / Neutral.